Nav1.7 inhibitors are primarily used in the development of treatments for pain management. They target the Nav1.7 sodium channel, which plays a crucial role in transmitting pain signals in the nervous system. By blocking this channel, these inhibitors can effectively reduce pain sensations, making them promising candidates for treating chronic pain conditions such as neuropathic pain, inflammatory pain, and inherited erythromelalgia. Additionally, they are being explored for their potential in addressing conditions like trigeminal neuralgia and other disorders associated with heightened pain sensitivity. Their specificity for the Nav1.7 channel aims to minimize side effects compared to broader sodium channel blockers. Research continues to optimize their efficacy and safety for clinical use.